Versant Capital Management, Inc Castle Biosciences Inc Transaction History
Versant Capital Management, Inc
- $710 Million
- Q3 2025
A detailed history of Versant Capital Management, Inc transactions in Castle Biosciences Inc stock. As of the latest transaction made, Versant Capital Management, Inc holds 181 shares of CSTL stock, worth $4,382. This represents 0.0% of its overall portfolio holdings.
Number of Shares
181
Previous 126
43.65%
Holding current value
$4,382
Previous $2,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding CSTL
# of Institutions
170Shares Held
27.9MCall Options Held
0Put Options Held
0-
Black Rock Inc. New York, NY3.04MShares$73.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.17MShares$52.5 Million0.0% of portfolio
-
Principal Financial Group Inc Des Moines, IA1.8MShares$43.6 Million0.02% of portfolio
-
Portolan Capital Management, LLC Boston, MA1.49MShares$36.1 Million2.2% of portfolio
-
Dimensional Fund Advisors LP Austin, TX1.38MShares$33.4 Million0.01% of portfolio
About CASTLE BIOSCIENCES INC
- Ticker CSTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 26,297,000
- Market Cap $637M
- Description
- Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...